• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗与转移性乳腺癌患者总生存的关系。

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer.

机构信息

Global Access, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Pharma International Informatics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

JAMA Netw Open. 2021 Jan 4;4(1):e2027764. doi: 10.1001/jamanetworkopen.2020.27764.

DOI:10.1001/jamanetworkopen.2020.27764
PMID:33439261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7807287/
Abstract

This cohort study compares the findings of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with those in the CLEOPATRA trial.

摘要

这项队列研究比较了曲妥珠单抗、帕妥珠单抗和多西他赛联合治疗转移性乳腺癌女性患者的结果与 CLEOPATRA 试验的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe9/7807287/4d80eb31bcd4/jamanetwopen-e2027764-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe9/7807287/4d80eb31bcd4/jamanetwopen-e2027764-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe9/7807287/4d80eb31bcd4/jamanetwopen-e2027764-g001.jpg

相似文献

1
Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer.帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗与转移性乳腺癌患者总生存的关系。
JAMA Netw Open. 2021 Jan 4;4(1):e2027764. doi: 10.1001/jamanetworkopen.2020.27764.
2
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌（CLEOPATRA）：一项双盲、随机、安慰剂对照、3 期研究的终期结果。
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
3
Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.帕妥珠单抗、曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌的疗效：一项荟萃分析
Int J Clin Pharmacol Ther. 2017 Sep;55(9):720-727. doi: 10.5414/CP202921.
4
Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.帕妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735.
5
In brief: Phesgo - a fixed-dose combination for HER-2 positive breast cancer.简而言之：帕妥珠单抗/曲妥珠单抗/透明质酸酶（Phesgo）——一种用于HER-2阳性乳腺癌的固定剂量组合药物。
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e43-e44.
6
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.皮下注射曲妥珠单抗联合帕妥珠单抗和多西他赛作为晚期HER2阳性乳腺癌的一线治疗方案
Anticancer Res. 2018 Nov;38(11):6565-6569. doi: 10.21873/anticanres.13023. Epub 2018 Nov 5.
7
Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.曲妥珠单抗联合帕妥珠单抗双重阻断HER2并联合放疗用于HER2阳性转移性或局部复发性不可切除和/或转移性乳腺癌：早期毒性评估
Cancer Radiother. 2017 Apr;21(2):114-118. doi: 10.1016/j.canrad.2016.10.002. Epub 2017 Mar 24.
8
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.在亚洲，曲妥珠单抗、帕妥珠单抗和多西他赛治疗早期或局部晚期 ERBB2 阳性乳腺癌患者的疗效、安全性和耐受性：PEONY 三期随机临床试验。
JAMA Oncol. 2020 Mar 1;6(3):e193692. doi: 10.1001/jamaoncol.2019.3692. Epub 2020 Mar 12.
9
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.帕妥珠单抗、曲妥珠单抗和紫杉烷类药物联合治疗内脏器官转移、曲妥珠单抗初治乳腺癌：真实世界的实践结果。
Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30.
10
[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].[帕妥珠单抗（Perjeta®）获批用于HER2阳性转移性乳腺癌]
Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940.

引用本文的文献

1
A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells.一种靶向LAG3和HER2的新型双特异性适体增强了针对HER2阳性癌细胞的T细胞介导的免疫疗法。
Front Immunol. 2025 Jul 21;16:1557910. doi: 10.3389/fimmu.2025.1557910. eCollection 2025.
2
Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort study.帕妥珠单抗在HER2阳性转移性乳腺癌患者中的真实世界疗效与安全性：一项基于加拿大全国人群的队列研究。
Int J Cancer. 2025 Sep 1;157(5):927-940. doi: 10.1002/ijc.35448. Epub 2025 Apr 23.
3

本文引用的文献

1
Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience.帕妥珠单抗治疗新加坡HER2阳性转移性乳腺癌的疗效、使用模式及成本：新加坡国立癌症中心的经验
World J Clin Oncol. 2020 Mar 24;11(3):143-151. doi: 10.5306/wjco.v11.i3.143.
2
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌（CLEOPATRA）：一项双盲、随机、安慰剂对照、3 期研究的终期结果。
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
3
Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice.
在常规临床实践中，帕妥珠单抗和曲妥珠单抗一线治疗晚期人表皮生长因子受体2阳性乳腺癌的疗效
World J Oncol. 2024 Jun;15(3):454-462. doi: 10.14740/wjon1829. Epub 2024 Apr 15.
4
Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.基于白细胞介素基因相关风险模型的乳腺癌免疫治疗综合评估及肿瘤微环境特征分析
Sci Rep. 2022 Nov 28;12(1):20524. doi: 10.1038/s41598-022-25059-8.
5
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.帕妥珠单抗联合化疗与曲妥珠单抗联合化疗治疗转移性乳腺癌的疗效和安全性比较。
JAMA Netw Open. 2022 Feb 1;5(2):e2145460. doi: 10.1001/jamanetworkopen.2021.45460.
6
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、帕妥珠单抗和多西他赛联合作为韩国HER2阳性转移性乳腺癌患者一线治疗的真实世界证据
Cancer Res Treat. 2022 Oct;54(4):1130-1137. doi: 10.4143/crt.2021.1103. Epub 2022 Jan 17.
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.免疫疗法在晚期非小细胞肺癌中的快速应用的真实世界进展、治疗和生存结果。
Cancer. 2019 Nov 15;125(22):4019-4032. doi: 10.1002/cncr.32383. Epub 2019 Aug 5.
4
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.一项关于曲妥珠单抗、帕妥珠单抗和紫杉类药物一线治疗晚期 HER2 阳性乳腺癌患者的多中心回顾性观察研究。RePer 研究。
Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.
5
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析：从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.
6
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.用于在ICD-9-CM和ICD-10管理数据中定义合并症的编码算法。
Med Care. 2005 Nov;43(11):1130-9. doi: 10.1097/01.mlr.0000182534.19832.83.